Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganitumab + Trastuzumab in HER2+ Metastatic Breast Cancer
NCT01479179Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2012
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of ganitumab in HER2-positive metastatic breast cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 21 days. Planned start Nov 2012; status: withdrawn.
02
Drugs
ganitumab
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT01479179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01479179.